Modeling the influence of non-adherence on antibiotic efficacy: Application to ciprofloxacin

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 8, 2007, Pages 438-447

  Lansky, P ^a   Sanda, P ^a   Weiss, M ^b  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Ciprofloxacin; Monte Carlo simulation; Nonadherence; Stochastic model

Indexed keywords

CIPROFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; MEDICATION ERROR; MINIMUM INHIBITORY CONCENTRATION; PATIENT COMPLIANCE; PHARMACODYNAMICS; SHORT COURSE THERAPY; SIMULATION;

EID: 34547849584     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45438     Document Type: Article

References (17)

1. Boissel J-P, Nony P. Using pharmacokinetic-pharmacodynamic relationship to predict effect of poor compliance. Clin Pharmacokinet. 2002; 41: 1-6.
2. Brixner DI. Improving acute otitis media outcomes through proper antibiotic use and adherence. Am J Manag Care. 2005; 11: 202-210.
3. Corvaisier S, Maire PH, d'Yvoire MYB, Barbaut X, Bleyzac N, Jelliffe RW. Comparison between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. Antimicrob Agents Chemother. 1998; 42: 1731-1737.
4. Czock D. Pharmacodynamic dose adjustment in renal failure: importance of the Hill coefficient. Int J Clin Pharmacol Ther. 2006; 44: 474-477.
5. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002; 49: 897-903.
6. Lipsitch M, Levin BR. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother. 1997; 41: 363-373.
7. MacGowan A, Rogers C, Bowker K. The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens. J Antimicrob Chemother. 2000; 46: 163-170.
8. Meagher AK, Forrest A, Dalhoff A, Stass H, Schentag JJ. Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob Agents Chemother. 2004; 48: 2061-2068.
9. Payen SR, Serreau R, Munck A, Aujard Y, Aigrain Y, Bressolle F, Jacqez-Aigrain E. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. Antimicrob Agents Chemother. 2003; 47: 3170-3178.
10. Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, Levin BR. Pharmacodynamic functions: a multi-parameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother. 2004; 48: 3670-3676.
11. Sanchez Navarro DM, Milano CC, Castaneda AZ, Sayalero Marinero ML, Sanchez Navarro A. Pharmacokinetic of ciprofloxacin as a tool to optimise dosage schedules in community patients. Clin Phamacokinet. 2002a; 41: 1213-1220.
12. Sanchez Navarro DM, Sayalero Marinero ML, Sanchez Navarro A. Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections. J Antimicrob Chemother. 2002b; 50: 67-72.
13. Tuckwell HC. Elementary applications of probability theory. London: Chapman and Hall; 1995. pp. 12.
14. Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother. 2005; 55: 616-627.
15. Wang S, Ouyang SP. The formulation of the principle of superposition in the presence of non-compliance and its applications in multiple dose pharmacokinetics. J Pharmcokinet Pharmacodyn. 1998; 26: 457-469.
16. Wiuff C, Zappala RM, Regoes RR, Garner KN, Baquero F, Levin BR. Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob Agents Chemother. 2005; 49: 1483-1494.
17. Wong D, Modi R, Ramanathan M. Assessment of Markov-dependent stochastic models for drug administration compliance. Clin Phamacokinet. 2003; 42: 193-204.